← Leaderboards
Adrianus G.w. Domen
Cellerant Therapeutics, Inc.
$658,973
Attributed
$1,317,946
Total exposure
2
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $573.6K · FY2013–19$1M$750K$500K$250K$0
'13
'14
'15
'16
'17
'18
'19
Funding mix
By agency
NIH$1,317,946 · 2
By mechanism
R42$1,117,159 · 1
R41$200,787 · 1
Top collaborators
- Swapna Panuganti2 shared
- Timothy Cheng Fong1 shared
Most similar at Cellerant Therapeutics, Inc.
Same institution · by research overlap
- Timothy Cheng Fong$100,394
- Swapna Panuganti$558,580
Others in their field
Top investigators on “Clinical Trials”
- Lawrence Corey · Fred Hutchinson Cancer Center$824,102,536
- Sonia M Thomas · Research Triangle Institute$700,865,642
- David Heimbrook · Leidos Biomedical Research, Inc.$622,583,125
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$542,008,718
- Bambra Strokes · Ppd Development Lp$526,656,217
- Judith S. Currier · University Of California Los Angeles$504,273,077
Research focus
Clinical TrialsHematopoietic Stem CellsClinical ApplicationClinical ProtocolsGraft RejectionHematopoietic Cell TransplantationCellsCitiesClinically RelevantAutologousExperimental ModelsFightingGraft SurvivalBiological ModelsAllogenicCell PhysiologyChildChimerismBone Marrow TransplantationAntigensBusinessesCardiopulmonaryEnd-Stage Organ FailureHematopoietic Stem Cell Transplantation
Grant awards (3)
Novel Indication for Myeloid Progenitor Use: Induction of Tolerance in Solid Organ Transplantation$543,567
R42 · FY2019 · AI
Novel Indication for Myeloid Progenitor Use: Induction of Tolerance in Solid Organ Transplantation$573,592
R42 · FY2018 · AI
Novel indication for myeloid progenitor use: Induction of tolerance$200,787
R41 · FY2013 · AI